Who
Prashant Kohli
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Grace Therapeutics.
In numbers
- Trades disclosed
- 8
- Buys
- 1
- Sells
- 0
- Bought
- $428K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Jul 2023
- Last trade
- 9 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 10 Sep 2026 | GRCE Grace TherapeuticsBiotechnology | SEC FORM 4 Bought | $214K100,000 at $2.14 | filing |
| 9 Sep 2026filed 10 Sep 2026 | GRCE Grace TherapeuticsBiotechnology | SEC FORM 4 Bought | $214K100,000 at $2.14 | filing |
| 28 Aug 2026filed 1 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —267,160 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —267,160 at $0.00 | filing |
| 14 Apr 2025filed 16 Apr 2025 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,400 at $0.00 | filing |
| 6 May 2024filed 8 May 2024 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —128,770 at $0.00 | filing |
| 19 Dec 2023filed 20 Dec 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,668 at $0.00 | filing |
| 14 Jul 2023filed 18 Jul 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —208,334 at $0.00 | filing |
News
Grace Therapeutics (NASDAQ:GRCE) Upgraded at Wall Street ZenGRCE · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Prashant Kohli; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.